Journal of Cancer Policy最新文献

{"title":"Integrating ePROMs: A key opportunity for England’s National Cancer Plan","authors":"Sally Wheelwright, Ollie Minton, Kate Absolom, Corinne Faivre-Finn, Lesley Fallowfield, Alexandra Gilbert, Duncan Gilbert, Alison Large, Thitikorn Nuamek, James Price, Tim Williams, Janelle Yorke, Valerie Shilling","doi":"10.1016/j.jcpo.2025.100575","DOIUrl":"10.1016/j.jcpo.2025.100575","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100575"},"PeriodicalIF":2.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding adjuvant drugs from distinct breast cancer trials.","authors":"Timothée Olivier, Vinay Prasad","doi":"10.1016/j.jcpo.2025.100568","DOIUrl":"10.1016/j.jcpo.2025.100568","url":null,"abstract":"<p><p>Studies conducted in perioperative settings have recently expanded the treatment options for early-stage operable breast cancer. These studies have different inclusion criteria, however they are not entirely mutually exclusive. It results that multiple treatment options may be available to the same patient, making the choice of therapy a significant challenge. The concurrent or sequential administration of these therapies has been suggested by expert panels or international guidelines. Yet combining therapeutic strategies that have been independently tested can be problematic. It is possible that the same subset of patients benefits from each therapy individually, meaning that combining them might offer no additional benefit. Moreover, the toxicity of those combinations - short and long-term - has not been assessed in phase 3 trials. Whether these toxicities and dose reductions offset gains is unknown. Here, we offer clinical scenario where this could happen, like combining pembrolizumab plus olaparib in triple-negative breast cancer, or olaparib plus CDK4/6 inhibitors in hormone receptor-positive disease. Although each therapy has shown efficacy in individual trials, the net gain of their combined or sequential use in the peri-operative setting remains unproven in phase 3 trials. This dilemma extends well beyond breast cancer as a growing number of agents continue to be approved in neoadjuvant or adjuvant space. A cautious evidence-driven approach is needed to ensure these strategies truly benefit patients. This could have important policy implications, including regulatory enforcement for combination trials rather than extrapolating from monotherapy data.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100568"},"PeriodicalIF":2.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-centered perspectives: Examining quality-of-life integration in recent phase III lung cancer trials (2019–2023)","authors":"Shreyas Kalantri ,&nbsp;Chiranjeevi Sainatham ,&nbsp;Greeshma N. Gaddipati ,&nbsp;Jayanth Reddy Tallapalli ,&nbsp;Rishabh Singh ,&nbsp;Goetz H. Kloecker","doi":"10.1016/j.jcpo.2025.100566","DOIUrl":"10.1016/j.jcpo.2025.100566","url":null,"abstract":"<div><h3>Background</h3><div>In the dynamic landscape of lung cancer treatment, marked by precision medicine advancements, addressing the persistent global health challenge of lung cancer requires nuanced evaluations beyond traditional endpoints like Overall Survival (OS). Both the US FDA and ASCO advocate for consistent integration of Quality of Life (QoL) and Patient-Reported Outcomes (PRO). This study evaluates the extent to which recent Phase III lung cancer trials incorporate QoL, highlighting implications for global cancer policy and research priorities.</div></div><div><h3>Methods</h3><div>This systematic review analyzed PubMed for Phase III lung cancer clinical trials involving anticancer drugs conducted between 2019 and 2023. The study assessed if QoL was included as an endpoint. Subgroup analyses categorized trials by cancer subtype (e.g., non-small cell lung cancer [NSCLC], small cell lung cancer [SCLC]). Analyses were also stratified by publication year to explore potential temporal trends. Subanalyses included impact factor categories (≥10 and &lt;10) and differentiation between superiority and noninferiority trials.</div></div><div><h3>Results</h3><div>191 Phase III lung cancer clinical trials published between 2019 and 2023, meeting the criteria were included in this study. QoL was included in 31.93 % of trials across all subtypes, 33.72 % of NSCLC trials incorporated QoL vs 19.04 % of SCLC trials included QoL. Our analysis reveals a significant shortfall in incorporating quality of life (QoL) as an endpoint, highlighting a crucial gap in evaluating the comprehensive impact of interventions.</div></div><div><h3>Conclusions</h3><div>The limited integration of QoL assessments in lung cancer trials underscores a missed opportunity to inform patient-centered care and highlights disparities across cancer subtypes. To address these gaps, global cancer policy should prioritize standardized QoL measures in clinical trial design. This shift is essential for aligning research with patient needs, ensuring equitable evaluation of treatment impacts, and advancing value-based care in oncology.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100566"},"PeriodicalIF":2.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capturing breast cancer subtypes in cancer registries: Insights into real-world incidence and survival","authors":"Larissa Vaz-Gonçalves ,&nbsp;Louise Marquart-Wilson ,&nbsp;Melinda M. Protani ,&nbsp;Meghan T. Stephensen ,&nbsp;Julie Moore ,&nbsp;Michelle F. Morris ,&nbsp;Jodi M. Saunus ,&nbsp;Marina M. Reeves","doi":"10.1016/j.jcpo.2025.100567","DOIUrl":"10.1016/j.jcpo.2025.100567","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer treatment is guided by diagnostic subtyping, yet cancer registries do not routinely capture this information, and real-world studies reporting subtype-specific incidence and survival do not reflect contemporary clinical management.</div></div><div><h3>Methods</h3><div>We analysed breast cancer incidence and survival using Queensland cancer registry data (2017–2019), stratifying by hormone receptor (HR) and HER2 status.</div></div><div><h3>Results</h3><div>Subtype-specific, age-standardised incidence rates were: 125.6 HR+/HER2- cases/100,000 women (76.0 % of all diagnoses), followed by 17.7/100,000 for triple-negative (TNBC; 10.3 %), 15.0/100,000 for HR+/HER2 + (8.7 %), and 8.6/100,000 for HR-/HER2 + (5.0 %). Compared to HR+/HER2-, all other subtypes had poorer breast cancer-specific survival (BCSS) and overall survival (OS; except HR +/HER2 + for OS) at 2-years, with OS associations attenuated but still significant for TNBC at 4-years. Stratifying by stage at diagnosis, TNBC had consistently poorer 2-year BCSS in those with stage I-III TNBC (HR_adj&gt;7), and marginally poorer in those with stage IV.</div></div><div><h3>Conclusions</h3><div>HR+/HER2- breast cancer is the most common subtype and has the best short-term prognosis. TNBC has markedly poorer short-term survival, even when diagnosed at an early stage. This study provides real-world data for benchmarking breast cancer incidence and survival, and highlights the importance of capturing receptor status and stage for cancer surveillance.</div></div><div><h3>Policy summary</h3><div>Routinely capturing breast cancer subtypes and stages in cancer registries needs to be prioritised to assess the real-world efficacy of evolving targeted therapies and to inform tailored surveillance for high-risk subtypes.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100567"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delivering quality cancer care in rural and coastal settings: Experiences of a large-scale integrated cancer transformation programme","authors":"David Nelson ,&nbsp;Kathie McPeake ,&nbsp;Samuel Cooke ,&nbsp;Ros Kane ,&nbsp;Peter Selby","doi":"10.1016/j.jcpo.2024.100544","DOIUrl":"10.1016/j.jcpo.2024.100544","url":null,"abstract":"<div><div><strong>Short introduction text:</strong> This abstract reports on the success of the system-wide, integrated Macmillan Living with Cancer Programme in the predominantly rural and coastal setting of Lincolnshire, England.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100544"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review of the association of ethnicity and cancer care pathways within Europe","authors":"Beth Russell ,&nbsp;Ailbhe Lawlor ,&nbsp;Lottie Phillips ,&nbsp;Sophie Pilleron ,&nbsp;Katrien Vanthomme ,&nbsp;Mieke Van Hemelrijck ,&nbsp;Ajay Aggarwal","doi":"10.1016/j.jcpo.2024.100546","DOIUrl":"10.1016/j.jcpo.2024.100546","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100546"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social inequalities in the return to work after lower gastrointestinal cancer following medical rehabilitation","authors":"Johannes Soff ,&nbsp;Ibrahim Demirer ,&nbsp;Clara Breidenbach ,&nbsp;Nicole Ernstmann ,&nbsp;Paula Heidkamp ,&nbsp;Lina Heier ,&nbsp;Kati Hiltrop ,&nbsp;Sophie Schellack ,&nbsp;Christoph Kowalski","doi":"10.1016/j.jcpo.2024.100542","DOIUrl":"10.1016/j.jcpo.2024.100542","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100542"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing early detection of ovarian cancer: A retrospective analysis using C the signs clinical decision support system","authors":"S. Dadhania ,&nbsp;R. Edgerley ,&nbsp;D. Milliken ,&nbsp;B. Bakshi ,&nbsp;M. Payling","doi":"10.1016/j.jcpo.2024.100552","DOIUrl":"10.1016/j.jcpo.2024.100552","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100552"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trials that treat what should be observed: SWOG 2308, a study of mosunetuzumab-axgb in asymptomatic low tumor burden follicular lymphoma","authors":"Myung Sun Kim ,&nbsp;Vinay Prasad","doi":"10.1016/j.jcpo.2025.100560","DOIUrl":"10.1016/j.jcpo.2025.100560","url":null,"abstract":"<div><div>S2308 is a study comparing rituximab, which is not the standard of care, to.mosunetuzumab-axgb, a first-in-class CD20-directed CD3 T-cell engager with.unknown long term side effects, in a heterogeneous patient population in which a fifth.of patients do not need treatment for at least 10 years. The treatment of asymptomatic.low tumor burden follicular lymphoma is watchful waiting and no treatment has.demonstrated improvement in OS after long term follow up. Beyond the limitations of.the study design, this study would be the basis of regulatory approval and cooperative.groups receiving federal funding should not be running this trial. Study sites are US based and mostly include community oncology practices, risking inclusion of very low.risk patients that are most likely to be harmed by any treatment</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100560"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: Enablers and barriers in implementing global cancer care efficiency metrics - A qualitative implementation study","authors":"Ana Sofia V. Carvalho ,&nbsp;Óscar Brito Fernandes ,&nbsp;Damir Ivanković ,&nbsp;Erica Barbazza ,&nbsp;Mădălina Iamandei ,&nbsp;Eduardo Pisani ,&nbsp;Niek Klazinga ,&nbsp;Dionne Kringos","doi":"10.1016/j.jcpo.2024.100543","DOIUrl":"10.1016/j.jcpo.2024.100543","url":null,"abstract":"<div><h3>Key category</h3><div>Health Systems &amp; Quality Cancer Care∼</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100543"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}